INM News & Events

InMed Pharmaceuticals announced the Company received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market dated March 27, 2026, notifying it that the closing bid price of the Company's common shares over a period of 30 consecutive trading days was below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) during the February 11, 2026 to March 26, 2026 period. In accordance with applicable Nasdaq procedures, the Company has a period of 180 calendar days following the receipt of the written notice mentioned above to cure the deficiency and regain compliance.

InMed Pharmaceuticals announced new preclinical data demonstrating the effects of INM-901 in reducing neuroinflammation in 3D human brain organoid models of Alzheimer's disease. These studies, conducted in collaboration with Stem Pharm, using their proprietary platform of human neuro-immune organoids, represent a key step in translating prior animal model results for INM-901 into a human-relevant system. Key Observations: INM-901 demonstrated significant reduction in neuroinflammation in Stem Pharm's LPS-induced model and in their Alzheimer's disease model. A dose-dependent reduction of key pro-inflammatory markers such as IL-6 and IL-8 was seen in both neuroinflammation models. Effects align with prior findings from an in vivo Alzheimer's model and an ex vivo LPS-induced neuroinflammation model. Provides supportive evidence of mechanistic translation from animal models to human tissue systems.

InMed Pharmaceuticals files $50M mixed securities shelf

InMed Pharmaceuticals provides a pharmaceutical development outlook for 2026. 2026 Development Priorities for INM-901 include: Conduct a pre-IND meeting with the U.S. Food and Drug Administration in Q3/2026. Continue to execute on IND-enabling pharmacology and toxicology studies. Continued development and scale up of drug substance and product manufacturing activities to support IND enabling studies and submission. Engage regulatory / clinical experts to map out topline clinical design for first in human clinical trials for the INM-901. Subject to regulatory feedback and completion of IND-enabling activities, the Company targets submission of an IND and initiation of a Phase 1 clinical trial in 2027. INM-089 Program Outlook - Scientific and development progress and plans include: Generation of data supporting continued evaluation of therapeutic potential. Completion of preclinical studies, including dose-ranging assessment, demonstrating dose proportionality and pharmacologically relevant concentration following dosing. Drug substance and drug product process in place to support IND enabling studies, with further optimization expected in advance of IND submission. Planning for a pre-IND meeting with the FDA in Q4 2026.